Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion.

Details

Ressource 1Request a copy Under indefinite embargo.
UNIL restricted access
State: Public
Version: author
License: CC BY-NC 4.0
Serval ID
serval:BIB_730329C0EF20
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion.
Journal
Neuro-oncology
Author(s)
Kotecha R., Sahgal A., Rubens M., De Salles A., Fariselli L., Pollock B.E., Levivier M., Ma L., Paddick I., Regis J., Sheehan J., Yomo S., Suh J.H.
ISSN
1523-5866 (Electronic)
ISSN-L
1522-8517
Publication state
Published
Issued date
05/03/2020
Peer-reviewed
Oui
Volume
22
Number
3
Pages
318-332
Language
english
Notes
Publication types: Journal Article ; Meta-Analysis ; Systematic Review
Publication Status: ppublish
Abstract
This systematic review reports on outcomes and toxicities following stereotactic radiosurgery (SRS) for non-functioning pituitary adenomas (NFAs) and presents consensus opinions regarding appropriate patient management.
Using the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses, a systematic review was performed from articles of ≥10 patients with NFAs published prior to May 2018 from the Medline database using the key words "radiosurgery" and "pituitary" and/or "adenoma." Weighted random effects models were used to calculate pooled outcome estimates.
Of the 678 abstracts reviewed, 35 full-text articles were included describing the outcomes of 2671 patients treated between 1971 and 2017 with either single fraction SRS or hypofractionated stereotactic radiotherapy (HSRT). All studies were retrospective (level IV evidence). SRS was used in 27 studies (median dose: 15 Gy, range: 5-35 Gy) and HSRT in 8 studies (median total dose: 21 Gy, range: 12-25 Gy, delivered in 3-5 fractions). The 5-year random effects local control estimate after SRS was 94% (95% CI: 93.0-96.0%) and 97.0% (95% CI: 93.0-98.0%) after HSRT. The 10-year local control random effects estimate after SRS was 83.0% (95% CI: 77.0-88.0%). Post-SRS hypopituitarism was the most common treatment-related toxicity observed, with a random effects estimate of 21.0% (95% CI: 15.0-27.0%), whereas visual dysfunction or other cranial nerve injuries were uncommon (range: 0-7%).
SRS is an effective and safe treatment for patients with NFAs. Encouraging short-term data support HSRT for select patients, and mature outcomes are needed before definitive recommendations can be made. Clinical practice opinions were developed on behalf of the International Stereotactic Radiosurgery Society (ISRS).
Keywords
Adenoma/radiotherapy, Disease Management, Humans, Pituitary Neoplasms/radiotherapy, Radiation Dose Hypofractionation, Radiosurgery/adverse effects, Societies, Medical, Treatment Outcome, ISRS, consensus, non-functioning, pituitary adenomas, radiation therapy, radiosurgery
Pubmed
Web of science
Open Access
Yes
Create date
04/12/2019 23:06
Last modification date
09/08/2024 15:51
Usage data